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Abstract. Microwave thermal ablation (MWTA) could 
be considered in the future for treating small solid renal 
masses. The aim of the present study was to determine both 
the tolerability of the new Amica-probe applicator-induced 
MWTA used in vivo on patients with solid renal masses 
and the effects of heating on renal tumors and normal renal 
parenchyma. Fourteen patients with renal masses eligible for 
open radical nephrectomy were enrolled in this phase I study. 
All patients underwent MWTA of renal masses during the 
open surgery procedure before clamping of renal vascular 
pedicle. The effects of MWTA on patients' coagulation and 
tumor/renal vasculature were investigated. The histological 
effects of MWTA on the tumor and intralesional vital tumor 
cell skipping were also evaluated. The MWTA-induced lesion 
diameters were measured to calculate both the overall ablation 
volume and the lesion sphericity index (SI). The Clavien-Dindo 
classification was used. In all patients the RENAL score was 
9.4 (8-12) and the Charlson comorbidity index was 4.8 (3-7). 
MWTA-induced lesion size was 44.14 mm (±22.59). Mean SI 
was 1.08 (±0.2). No significant differences among coagula-
tion clinical parameters were found. No local bleeding after 
MWTA treatment was reported. According to the Clavien-
Dindo classification, there were two grade II perioperative 
complications due to the tumor extent but not related with the 
MWTA treatment. No residual vital tumor cells inside the 
MWTA-induced lesions were found. Telephone interview at 
27.4 (±4.2) months mean follow-up did not find any long-term 
adverse events due to previous MWTA treatment. Amica-
Probe applicator-induced MWTA is a safe and reproducible 
method to treat solid renal masses.
Introduction
Prevalence of small solid renal masses in adult population 
recently increased probably due to the large number of people 
that daily undergo preventive diagnostic investigations such 
as ultrasonography and computed tomography (CT) scan for 
unrelated symptoms, resulting in incidental tumor detection 
(1). Patients' comorbidities, such as cardiovascular or respira-
tory diseases, could represent limiting factors for planning 
adequate subsequent surgical approaches although conserva-
tive laparoscopy surgery is now considered the gold standard 
treatment, particularly for tumors <3-4 cm (2). Minimally 
invasive procedures, such as cryoablation (CryA) and radio-
frequency ablation (RFA), have been recently proposed 
by different authors as alternative methods of treatment to 
conservative surgery with satisfactory results in terms of 
perioperative complications such as hemorrhage episodes or 
metabolic problems related to prolonged period of general 
anaesthesia (3). Some doubts remain on the efficacy of these 
methods on tumor complete eradication due to the high 
prevalence of tumor local recurrences due to persistent vital 
tumor cells in the context of the ablated tissue (tumor skip-
ping) (4). Both CryA and RFA are based on the application 
of physical means (cold and heat respectively) at the centre 
of the lesion to induce tumor tissue necrosis. Both of them 
are suitable for clinical application either through laparoscopic 
trocars or ultrasound/CT-guided percutaneous approaches 
(5). Microwaves are a source of electromagnetic energy 
which, similarly to radiofrequency or cryoablation, could be 
considered in the future for treating small solid renal masses 
percutaneously or laparoscopically (5). Indeed, with respect to 
RFA and CryA, microwave thermal ablation (MWTA) allows 
for a more rapid and homogeneous ablation, due to its reduced 
sensitivity to local variations of tissue physical properties (6,7). 
We previously studied the in vivo effects of MWTA on porcine 
kidney, proving that MWTA is a safe and effective procedure. 
In particular, we demonstrated the absence of viable cells 
inside the ablation volume and the absence of any damage 
to the renal parenchyma outside it (8). Although empirical 
studies on the effects of MWTA in the treatment of small renal 
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masses were previously reported by other authors on small 
series of patients, none of them reported adequate informa-
tion on patients tolerability and pathological effects on ablated 
tissues (4,5). The aim of this phase I prospective multicentre 
study was to determine both the tolerability of the new Amica-
probe V4 applicator-induced MWTA administered in vivo on 
patients with solid renal masses and the effects of heating on 
the renal tumors and normal renal parenchyma.
Materials and methods
Study design. From February 2009 to June 2010, 14 consecu-
tive patients affected by solid renal masses eligible for open 
radical surgical treatment were enrolled in three different 
Italian Urological Centers. We considered for enrolling only 
patients with renal masses who were candidates to open 
radical nephrectomy in order to obtain useful adjunctive 
information on both the anatomical extent and the distribution 
of MWTA on tumor and peritumoral healthy renal tissues. 
The patients underwent standard laboratory examinations 
and radiological evaluations before the treatment. The effects 
of MWTA on patients' coagulation, tumor/renal parenchyma 
and tumor skipping were assessed. Patients were informed on 
the risk of a new therapy with no long-term follow-up data 
and agreed to participate in the study. The present study was 
approved by the Research Ethics Committee in each of the 
Centers participating in the study (IRB Coordinator Center 
no. URO/01/2008-322/2008). Written informed consent was 
obtained from all patients before treatment. The study was 
conducted in line with Good Clinical Practice guidelines and 
with the Ethical Principles laid down in the latest version of 
the Declaration of Helsinki.
Inclusion and exclusion criteria. Requirements for inclu-
sion were the presence of a single, solid, contrast-enhanced 
parenchymal renal mass (attenuation increase, >15 H on 
contrast-enhanced CT or >15% on gadolinium-enhanced MRI) 
consistent with renal cell carcinoma on preoperative imaging 
and to be scheduled for radical nephrectomy through an open 
approach (9). Patients affected by major concomitant diseases 
that precluded the surgical treatment, ASA score ≤3, poor 
performance status (ECOG, 3-4), previous abdominal major 
surgery, severe medical or psychiatric illness that precluded 
adequate informed consent, <18 or >85 years, who had under-
gone radiation therapy to the retroperitoneum were excluded.
RENAL score and Charlson comorbidity index. The RENAL 
nephrometry score was calculated in accordance with Kutikov 
and Uzzo (10). In brief, standardized points (1-3 points/
descriptor) were assigned based on tumor size, endophytic/
exophytic properties, nearness to collecting system and lesion 
location relative to polar lines. Moreover, the Charlson comor-
bidity index was calculated by using the software purposed 
in the website of the Institute for Algorithmic Medicine 
(Texas non-profit Corporation) (http://www.medal.org/
OnlineCalculators/ch1/ch1.13/ch1.13.01.php) (11).
Microwave probe applicator. The system used for MWTA was 
HS AMICA, with the Amica-probe V4 applicator (Hospital 
Services SpA, Aprilia, Italy), which is a technical development 
of a previously described applicator (Amica-probe V3) (12). 
Amica-probe V4 includes a coaxial antenna and an integrated 
hydraulic circuit to cool the coaxial feeding line. The antenna 
is provided with a patented device (minichoke) for the entrap-
ment of back-propagating waves and is terminated by a sharp 
point for easy penetration into the tissues (Fig. 1). Control over 
the coagulative lesion size is obtained by setting the micro-
wave power level and delivery time.
Surgical treatment and MWTA. After the surgical exposure 
of the kidney and before vascular renal pedicle clamping, a 
Tru-cut biopsy specimen was taken from the tumor, in order to 
obtain a tumor sample for histopathological analysis. Then, the 
Amica-probe V4 applicator was inserted in the bed of Tru-cut 
needle into the tumor. The applicator was placed at least 3 cm 
deep into the tumor, for tumor size >4-5 cm (calculated on 
the basis of CT scan resolution), and at least 1 cm beyond 
the tumor, in the case of tumor size <4 cm. Such different 
applicator insertion methods were used in order to verify the 
complete tumor ablation in subjects with tumor size <4 cm. 
For each patient, 50 W microwave power was delivered into 
the renal tissue for 5 min. The selection of power and time of 
exposure to MWTA was determined on the basis of previous 
studies on porcine kidney where these two parameters were 
standardized to obtain spheroidal shaped repeteable lesions 
(8). The probe was removed, the renal blood vessels were 
promptly legated and the surgeon proceeded to classic radical 
nephrectomy. The surgical specimen, consisting of the kidney 
and tumor within the Gerota fascia, was removed en bloc and 
underwent pathological analysis for standard hystopatho-
logical diagnosis, microwave thermo-induced effects in the 
context of both tumor and healthy renal tissue and tumor 
skipping evaluation.
Heating-induced lesion measurement and histopathological 
analysis. Pathological samples were collected from the ablated 
tissues immediately after surgery to investigate neoplastic vital 
cell skipping. Small tumor samples were collected from the 
tumor bed after adequate sagittal and horizontal line kidney 
sections useful for both the tumor and the microwave thermo-
induced lesion measurements. These small samples were 
immediately sectioned and stained with trypan blue according 
to the procedure described by Allison and Ridolpho (13), in 
order to test cell viability. Pathologist thus provided for tumor 
and lesion measurements and tissues were stored in formalin for 
subsequent staining with haematoxylin and eosin (H&E) and 
microscopical analysis. Pathological evaluation was carried 
out by one dedicated pathologist in each center, in accordance 
with Bartoletti et al (8). All samples were analyzed to evaluate 
the effect of microwave energy delivered to renal tissue (no 
Figure 1. Sagittal section of Amica-probe V4.
ONCOLOGY REPORTS  28:  1243-1248,  2012 1245
skipping) and the effect of energy on the collecting system or 
peritumoral healthy renal tissue, as previously described (8). 
All ablation lesions were assessed using callipers for both the 
short-axis diameter (r1, perpendicular to the applicator) and the 
long-axis diameter (r2, along the applicator). In addition, both 
diameters were used to calculate the sphericity of the ablation. 
Sphericity index (SI) was defined as the volume of ablation 
divided by the volume sphere, using only the greatest diameter. 
According to Hines-Peralta et al (14), the volume of ablation 
was defined as the calculated volume of an ellipsoid, obtained 
by using r1 and r2 radii. As suggested by these authors, SI was 
simplified to r12/r2 (2); a perfect sphere has an index of 1.0 and 
an ellipsoid <1.0 (14).
Trypan blue exclusion test. Trypan blue exclusion test (Life 
Technologies) is able to accurately determine cell viability. 
In fact, if cells take-up trypan blue, they are considered non-
viable. Live cells or tissues with intact cell membranes are not 
colored. After the Amica-probe application, a sample of the 
renal lesion was collected and immediately sent to laboratory 
in isotonic salt solution under refrigerate conditions. Renal 
cells were added to a solution 0.4% of trypan blue in buffered 
isotonic salt solution, pH 7.2-7.3, such as phosphate-buffered 
saline and were examined immediately under a microscope 
at low magnification. In order to obtain reproducible results, 
the sample collection and tissue processing was performed 
according to Wu et al (15).
Preoperative complication evaluation. The classification of 
perioperative complications was performed using the Clavien-
Dindo classification (16).
Statistical analysis. All ablation diameters are reported as the 
mean (±SD) and were compared using ANOVA, followed by 
Bonferroni test, when appropriate, with P<0.05 (two-sided) 
considered to indicate significance. All statistical calcula-
tions were performed with the Statistical Package for Social 
Sciences 11.0 (SPSS, Inc., Chicago, IL, USA).
For the ablation equipment, materials, support was provided 
by Hospital Services SpA, and the results were analyzed 
and discussed independently of any influence of the Sponsor 
Company.
Results
Fourteen patients (12 men and 2 women; mean age, 70.9±9.8; 
range, 53-88 years) underwent open radical nephrectomy. 
The mean age-adjusted Charlson comorbidity index was 4.8 
(range, 3-7). The mean RENAL score was 9.4 (range, 8-12). 
Table I shows the clinical and laboratory characteristics of 
enrolled patients.
Clinical and laboratory results. No significant differences 
between D-dimer, aPPT and INR values were found before 
and after MWTA and surgery treatment independently 
from previous anti-platelet medical treatments. Two patients 
(14.2%) with tumor extension to vena cava (pT3b), showed 
low grade complications (Clavien II) that required blood 
transfusions. This procedure was, however, independent from 
the parenchyma MWTA treatment. All patients had a normal 
postoperative time of hospitalization (mean, 3.1 days; range, 
3-5) without relevant complications concerning both the 
wound healing and the laboratory analyses regularization. No 
short-term significant bleeding was collected from draining 
tubes which were removed just before patient discharge. No 
adverse events due to co-morbidities were observed during 
hospitalization or after long-term follow-up (27.4±4.2 months). 
Noticeable absence or reduction bleeding from the tumor 
was described by different surgeons overall in patients with 
smaller tumors, although this parameter could not be scientifi-
cally quantifiable.
Histopathological results
Macroscopic evaluation. MW-induced lesion size was 
44.14 mm (±22.59). All removed kidneys were sectioned 
along three different planes (sagittal, orizontal and trans-
versal) in order to obtain precise measurement of both tumor 
and MWTA-induced lesion diameters. Mean SI of MWTA-
induced lesions was 1.08 (±0.2). Fig. 2 shows the distribution 
of SI values among all patients. All pathological and labo-
ratory findings are presented in Table II. The inner area of 
the MWTA-induced lesions appeared pale and necrotic, the 
middle area hyperemic, while a purple border represented the 
outer layer. H&E staining showed homogeneous coagulative 
necrosis at the lesion core (inner area) surrounded by renal 
cells (Fig. 3A).
Table I. Patient characteristics at baseline.
Characteristics Mean SD Median Range
Age (years) 70.9 9.8 70 53-88
Charlson CI  4.8  1.2  4 4-7
Lesion diameter (mm) 47.00 18.7 44 40-92
RENAL score  9.4  1.1  9 8-12
D-dimer (mg/l) 226.8 87 225.5 102.5-433.3
INR 1.01 0.08 0.95 0.89-1.11
aPTT 31  3.9 30.5 23-37.5
Enrolled patients, n=14 (12 males, 2 females). SD, standard deviation; Charlson CI, Charlson comorbidity index.
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Microscopic evaluation. Renal cells appear with irre-
versible cell death, as shown by pyknotic nuclei and nuclear 
disruption. There were variable amounts of granulation tissue, 
with immature fibroblasts and inflammatory cells in the 
boundary region (middle and outer areas). Beyond these, only 
healthy tissue was found and no skipping was noted in any 
sample (Fig. 3B). Moreover, histological review of the wide 
ablation zones showed the inner zone to have uniform cell 
death by trypan blue exclusion test. No residual vital tumor 
cells inside the MW-induced lesions were found.
Discussion
The effects of MWTA on kidney tissue have been recently 
evaluated and discussed by several authors with conflicting 
results. Clark et al (9) demonstrated the feasibility of MWTA 
in 10 patients with large kidney tumors before radical nephrec-
tomy and demonstrated complete tumor cell kill inside the 
ablated lesions. Liang et al (17) confirmed the efficacy of 
MWTA on renal tumors by treating 12 patients with small 
lesions (<4 cm in diameter) and no evidence of recurrence 
after 20 months of follow-up, while Castle et al (18) reported 
poor oncologic outcomes and significant complication rates 
in a series of 10 patients with tumor diameter size ranging 
from 2.0 to 5.5 cm treated by laparoscopic- or CT-guided 
percutaneous MWTA. Rational explanations for such similar 
discrepancies could be easily found by evaluating either the 
absence of a standardized and reproducible method for micro-
wave administration or the adequate selection of patients. 
Our previous study on porcine kidney (8) demonstrated that 
a standardized method of microwave administration could 
be obtained by using pre-determined independent variables 
such as power of treatment and time of exposure to energy. 
The Amica-probe antenna is a new refrigerated probe able to 
determine approximately spherical lesions with a maximum of 
2.7±0.3 cm in the animal kidney tissue by an exposure time of 
5 min and 50 W power (8). The best results could be obtained 
by using 15 min of time exposure and 50 W power with 
induced-lesion SI ~1.0 and diameters from 4.1 to 4.2 cm (±0.1). 
Moreover, the thermocouple sensors placed ~4 cm radially 
far from the Amica-probe antenna point of insertion showed 
temperature peaks of 41˚C, thus, confirming the safety of this 
method on healthy renal tissues. These results could explain 
the importance of patient selection (only patients with small 
renal masses could be treated) and reliable technology (this 
refrigerated probe is able to induce a satisfactory SI) to obtain 
Figure 3. Pathological findings after micro-wave-thermal-ablation (H&E; 
magnification, x40). (A) Gross inspection of the ablated kidney tissue. 
(B) Three areas of ablation were noted when compared to the peripheral 
normal-looking parenchyma (NT). The inner area appeared pale and necrotic 
(N), the middle area hyperemic (HYP), while the outer layer is represented 
by a purple border (PB).
Table II. Pathological and laboratory findings after treatment.
Pathological findings
Histological findings 13 RCC
 1 oncocytoma
Pathological stage   2 T1a
   5 T1b
 1 T2
   3 T3a
    2 T3b




Complications 2, grade II
(Clavien grade)
Laboratory findings Mean  Difference (P-value)
D-dimer pre (mg/l) 226.85 0.21
D-dimer post (mg/l) 445.69
INR pre 1.01 0.92
INR post 1.10
aPTT pre 31 0.34
aPTT post 31.69
RCC, renal cell carcinoma.
Figure 2. Distribution of sphericity index values among all treated patients.
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reproducible methods of treatment and evaluable results. This 
is the first study describing the use of Amica-probe V4 micro-
wave applicator on human kidney tumors, which has been 
successfully tested. Although a subjective variability of MWs 
induced lesion diameters due to both the applicator insertion 
depth and the tumor water content, tumors until 2 cm could be 
safely treated by using 50 W power energy and 5 min of expo-
sure time to MWs. Clinical studies on MWTA of small renal 
masses and conservative surgery should be then conducted to 
obtain extensive clinical clarifications and indications on this 
fascinating technique. Microwaves create a thermal field that 
is absorbed by surrounding tissues proportionally to the tissue 
water content (19). Thus, tissues with greater water content 
absorb more energy and produce heat, while tissues with lower 
water content produce less heat and propagate microwaves (20). 
Testing the Amica-probe antenna on both healthy renal tissue 
and renal tumor tissue, we found no substantial differences 
of diffusion of MWs by measuring macroscopically MWTA-
induced lesion diameters, although no significant variations 
of SI were found. This could be related to both the cellular 
type or the presence of necrosis in the context of the tumor. 
Nevertheless, large tumors usually present necrotic areas in 
their context while small tumors tends to be more compact and 
homogeneous except oncocytomas. All patients selected for 
this study presented large or complicated renal masses (mean 
RENAL score, 9.4). This kind of selection aimed to obtain an 
accurate evaluation of MWs diffusion and spread inside the 
tumor tissue, thus, avoiding the risk of significant variations in 
heat-induced lesion diameters due to different tissue resistance 
of tumor pseudo-capsule. Nevertheless, this could justify future 
studies on MWTA application on small solid renal masses. 
The potential tropism of MWs to tumor and renal vasculature 
represented one of the most important parameters investigated 
in this study. No differences were found in monitoring the 
patients haemo-coagulative set up before surgery and after 
short- and long-term follow-up, showing a limited diffusion 
of MWs through renal tissue independently from the renal 
pedicle clamping during the MWTA treatment. All patients 
underwent open radical nephrectomy after MWTA treatment 
and only 2/14 of them presented intraoperative bleeding with 
the need of blood-transfusions due to the presence of a tumor 
thrombus in the vena cava (Clavien II). The incidence of 
patients requiring blood-transfusions during radical nephrec-
tomy have been reported as ranging from 18 to 44% in relation 
to tumor extension and the need of extensive surgery (21). This 
complication found in our series has not to be considered as 
relevant and it was not related to the MWTA tumor treatment. 
No evidence of tumor-cell skipping was found by using vital 
staining analyisis in all cases. This could demonstrate that 
local recurrence of disease, previously described by other 
authors, is probably due to the incomplete ablation of large 
tumors where the estimation of surgical results have been 
entrusted to the macroscopically apparent evidence of ablation 
in case of both laparoscopic- and CT-guided MWs applica-
tion. The empirical experience of Muto et al (22) confirmed 
our results demonstrating that MWs application to small renal 
tumors (1.3-4.2 cm) provides good results in terms of tumor 
follow-up and has to be considered as optimal method for 
haemostasis making laparoscopic tumor enucleation easier 
and possible without renal pedicle clamping and haemostatic 
sutures subsequent to tumor removal. However, the present 
study shows few limitations that should be taken into account 
during interpretation of the findings. The MWs diffusion and 
spread through tumor tissue may vary in relation to its liquid 
content (water and/or necrosis), thus, large tumors could not 
be considered as the optimal model although our findings 
demonstrated satisfactory homogeneous results in terms of 
both heat-induced lesion diameters and SI.
In conclusion, the Amica-probe V4 microwave antenna 
is able to determine reproducible results in the treatment of 
small kidney solid tumors. MWTA is a safe method and could 
be relatively easily employed for future clinical efficacy and 
comparative studies.
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